Lorlatinib shrinks rare brain tumour in child after the standard of care fails.
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on February 01, 2023 03:22 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 337510354 series 3382249
Conteúdo fornecido por Andrew Scarborough. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Andrew Scarborough ou seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
8-year-old Deliah Sitorius had been fighting a rare brain cancer for almost a year with chemotherapy . Unfortunately this was unsuccessful and she stopped treatment immediately. Deliah was given hope after her mother discovered the tumour has a rare mutation often seen in lung cancer. Since applying a more targeted, personalised approach using a drug called Lorlatinib the tumour has been shrinking.
Loratinib is a third generation ALK ROS1 tyosine kinase inhibitor, specifically designed to overcome known ALK resistance mutations. It is able to penetrate the blood brain barrier and more recently we have seen paediatric brain cancer patients who are responding very well to the drug.
21 episódios
Compartilhar
))
